MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model

scientific article published in November 2002

MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0969-8051(02)00346-3
P698PubMed publication ID12453586

P2093author name stringMichael J Welch
Lynne A Jones
Terry L Sharp
John A Engelbach
Nobuyuki Oyama
Joonyoung Kim
Nicole M Mercer
P2860cites workCancer statistics, 2002Q28216788
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells.Q40813713
Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imagingQ43666964
FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation.Q43707212
Biological determinants of cancer progression in men with prostate cancer.Q51090543
Uptake and retention of androgens by the rat ventral prostate and consideration of their use as site directing agentsQ67242422
Synthesis of [1-11C], [2-11C], [1-11C](2H3) and [2-11C](2H3)acetate for in vivo studies of myocardium using PETQ73537277
Performance evaluation of the microPET P4: a PET system dedicated to animal imagingQ74272637
P433issue8
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
P304page(s)783-790
P577publication date2002-11-01
P1433published inNuclear Medicine and BiologyQ7067979
P1476titleMicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model
P478volume29

Reverse relations

cites work (P2860)
Q4462902511C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.
Q3809844118F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients
Q33945133Challenges in clinical prostate cancer: role of imaging
Q39512219Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?
Q48325806Early Response Monitoring Following Radiation Therapy by Using [18F]FDG and [11C]Acetate PET in Prostate Cancer Xenograft Model with Metabolomics Corroboration
Q39650275Early response assessment in prostate carcinoma by 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models
Q40275645Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model
Q37352995FDG PET in Prostate Cancer
Q39335098Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors.
Q44827523Is 11C-choline the most appropriate tracer for prostate cancer? Against
Q53525226Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model.
Q35904989Microenvironmental and cellular consequences of altered blood flow in tumours
Q37325974Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.
Q53359744Molecular imaging of prostate cancer.
Q26765882Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring
Q34164758Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.
Q38297700Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
Q37310963Serially heterotransplanted human prostate tumours as an experimental model
Q26996477The potential of ¹¹C-acetate PET for monitoring the Fatty acid synthesis pathway in Tumors
Q34633685Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor
Q36533822Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.
Q46804582[(11)C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy
Q39698461[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model
Q37085677[F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland